MedTrace Logo

Registry of Irreversible Electroporation for the Ablation of Prostate Cancer With Use of Nanoknife Device

NCT02255890 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 361

Last updated 2020-12-14

No results posted yet for this study

Summary

The aim of this registry is to assess the recurrence of prostate cancer at 1 and 5 years, as well as the change in functional outcomes (e.g. incontinence or erectile function) from baseline. Secondary objectives are to establish which indications lead to treatment with IRE Nanoknife® setting and safety assessment measured by number of complications and adverse events.

Conditions

Sponsors & Collaborators

  • Clinical Research Office of the Endourological Society

    lead OTHER

Principal Investigators

  • Jean de la Rosette · Clinical Research Office of the Endourological Society

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2020-06-30
Completion
2025-04-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02255890 on ClinicalTrials.gov